CN1150915C - 一种治疗心血管病的药物及其制作方法 - Google Patents
一种治疗心血管病的药物及其制作方法 Download PDFInfo
- Publication number
- CN1150915C CN1150915C CNB001113038A CN00111303A CN1150915C CN 1150915 C CN1150915 C CN 1150915C CN B001113038 A CNB001113038 A CN B001113038A CN 00111303 A CN00111303 A CN 00111303A CN 1150915 C CN1150915 C CN 1150915C
- Authority
- CN
- China
- Prior art keywords
- medicine
- water
- parts
- treatment cardiovascular
- artificial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 9
- 239000006187 pill Substances 0.000 title claims abstract description 6
- 230000008569 process Effects 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 85
- 229940079593 drug Drugs 0.000 claims abstract description 23
- 239000004615 ingredient Substances 0.000 claims abstract description 22
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 17
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 14
- 235000005412 red sage Nutrition 0.000 claims abstract description 14
- 239000007788 liquid Substances 0.000 claims abstract description 13
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 5
- 235000008434 ginseng Nutrition 0.000 claims abstract description 5
- 239000002826 coolant Substances 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 15
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 14
- 238000005516 engineering process Methods 0.000 claims description 14
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 13
- 229960001661 ursodiol Drugs 0.000 claims description 13
- VOZHMAYHYHEWBW-NVOOAVKYSA-N Bufotalin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]3(O)C[C@@H]2OC(=O)C)C=CC(=O)OC=1 VOZHMAYHYHEWBW-NVOOAVKYSA-N 0.000 claims description 11
- VOZHMAYHYHEWBW-UHFFFAOYSA-N Bufotalin Natural products CC(=O)OC1CC2(O)C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 VOZHMAYHYHEWBW-UHFFFAOYSA-N 0.000 claims description 11
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 11
- 229930182494 ginsenoside Natural products 0.000 claims description 10
- 229940089161 ginsenoside Drugs 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 8
- 230000004927 fusion Effects 0.000 claims description 7
- 229920002545 silicone oil Polymers 0.000 claims description 7
- 230000001804 emulsifying effect Effects 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000003177 cardiotonic effect Effects 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 3
- 229930182490 saponin Natural products 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- 229930182470 glycoside Natural products 0.000 claims description 2
- 150000002338 glycosides Chemical class 0.000 claims description 2
- 239000002075 main ingredient Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 3
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 238000009413 insulation Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 5
- 241000208340 Araliaceae Species 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 abstract description 3
- 239000003921 oil Substances 0.000 abstract description 3
- 229910052710 silicon Inorganic materials 0.000 abstract description 3
- 239000010703 silicon Substances 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 241000196324 Embryophyta Species 0.000 abstract 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 206010004542 Bezoar Diseases 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 239000003088 amphibian venom Substances 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 238000000265 homogenisation Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 5
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 5
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000000857 drug effect Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000007962 solid dispersion Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- KBKUJJFDSHBPPA-UHFFFAOYSA-N 5beta-hydroxylcinobufagin Natural products CC(=O)OC1C2OC22C3CCC4(O)CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 KBKUJJFDSHBPPA-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 2
- XEUCQOBUZPQUMQ-UHFFFAOYSA-N Glycolone Chemical compound COC1=C(CC=C(C)C)C(=O)NC2=C1C=CC=C2OC XEUCQOBUZPQUMQ-UHFFFAOYSA-N 0.000 description 2
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- KBKUJJFDSHBPPA-ZNCGZLKOSA-N cinobufotalin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@@]5(O)CC[C@H]4[C@@]43O[C@@H]4[C@@H]2OC(=O)C)C=CC(=O)OC=1 KBKUJJFDSHBPPA-ZNCGZLKOSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000004451 qualitative analysis Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 229930190011 Bufogenin Natural products 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- FMTLOAVOGWSPEF-KJRPADTMSA-N Gamabufogenin Chemical compound C=1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC4)C)[C@H](O)C[C@@]32C)C=CC(=O)OC=1 FMTLOAVOGWSPEF-KJRPADTMSA-N 0.000 description 1
- FMTLOAVOGWSPEF-UHFFFAOYSA-N Gamabufotalin Natural products CC12CC(O)C(C3(CCC(O)CC3CC3)C)C3C1(O)CCC2C=1C=CC(=O)OC=1 FMTLOAVOGWSPEF-UHFFFAOYSA-N 0.000 description 1
- ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical compound C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- QFJUYMMIBFBOJY-UXZRXANASA-N Panaxatriol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(C[C@@H](O)[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 QFJUYMMIBFBOJY-UXZRXANASA-N 0.000 description 1
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- ATLJNLYIJOCWJE-CWMZOUAVSA-N bufogenin Chemical compound C=1([C@H]2C[C@H]3O[C@@]43[C@H]3[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC3)C)CC[C@@]42C)C=CC(=O)OC=1 ATLJNLYIJOCWJE-CWMZOUAVSA-N 0.000 description 1
- 229950006858 bufogenin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- -1 or fat-soluble Substances 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 208000023482 precordial pain Diseases 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001113038A CN1150915C (zh) | 2000-08-25 | 2000-08-25 | 一种治疗心血管病的药物及其制作方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001113038A CN1150915C (zh) | 2000-08-25 | 2000-08-25 | 一种治疗心血管病的药物及其制作方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1340344A CN1340344A (zh) | 2002-03-20 |
CN1150915C true CN1150915C (zh) | 2004-05-26 |
Family
ID=4581224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB001113038A Expired - Fee Related CN1150915C (zh) | 2000-08-25 | 2000-08-25 | 一种治疗心血管病的药物及其制作方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1150915C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1297288C (zh) * | 2003-11-19 | 2007-01-31 | 王锦刚 | 一种治疗心血管疾病的药物及其制备方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104107219B (zh) * | 2014-07-18 | 2018-07-27 | 长春中医药大学 | 一种治疗冠心病心绞痛的气雾剂及其制备工艺 |
CN109125390A (zh) * | 2018-09-29 | 2019-01-04 | 内蒙古康恩贝药业有限公司圣龙分公司 | 一种麝香通心滴丸及其制备方法 |
-
2000
- 2000-08-25 CN CNB001113038A patent/CN1150915C/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1297288C (zh) * | 2003-11-19 | 2007-01-31 | 王锦刚 | 一种治疗心血管疾病的药物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1340344A (zh) | 2002-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1704085A (zh) | 一种具有免疫调节作用的药物组合物及其制备方法 | |
CN1247241C (zh) | 六味地黄滴丸 | |
CN1879868A (zh) | 一种治疗妇女痛经的药物及其制备方法 | |
CN1895222A (zh) | 一种微乳液及其载药制剂的制备方法及应用 | |
CN1150915C (zh) | 一种治疗心血管病的药物及其制作方法 | |
CN1850167A (zh) | 一种消渴降糖滴丸及其制备方法 | |
CN109700856A (zh) | 一种具有活血通络、舒筋止痛的中药外用方剂 | |
CN1297288C (zh) | 一种治疗心血管疾病的药物及其制备方法 | |
CN1087275A (zh) | 治疗缺血性脑、心血管制剂舒脉宁 | |
CN1698717A (zh) | 一种中药复方脂肪乳注射液及其制备方法 | |
CN1107501C (zh) | 阿苯达唑乳剂 | |
CN1596983A (zh) | 纳米sod与人参或其提取物的组合物及其制备方法 | |
CN1544065A (zh) | 一种感冒清热泡腾片剂及其制备方法 | |
CN107496831A (zh) | 一种高效吸收中药成分的通经保元膏 | |
CN101642536B (zh) | 用于治疗骨质增生的膏药 | |
CN100339133C (zh) | 纳米sod与纳米黄芪的组合物 | |
CN1270736C (zh) | 一种治疗阳痿的中药组合物及其制备方法和质量控制方法 | |
CN1425412A (zh) | 复方血栓通口服制剂及其制备方法 | |
CN1759858A (zh) | 复方独一味滴丸的处方及其制作方法 | |
CN1762419A (zh) | 独一味滴丸的处方及其制作方法 | |
CN1362239A (zh) | 纳米益血生制剂药物及其制备方法 | |
CN1650962A (zh) | 一种用于治疗心律失常的中药制剂及其制备方法 | |
CN101085296B (zh) | 一种冻干粉针剂及其制备方法 | |
CN1762433A (zh) | 一种新的治疗骨折药物的处方及制作方法 | |
CN1823947A (zh) | 脑得生制剂及新的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: INNER MONGOLIA YITAI BIOLOGICAL HI-TECH CO., LTD. Free format text: FORMER OWNER: SUN MINFU Effective date: 20040827 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20040827 Address after: 017000 Erdos West Street, Erdos District, Inner Mongolia, Dongsheng Patentee after: Inner Mongolia Yitai bio Tech Co. Ltd. Address before: 264006 No. 5, Yanshan Road, Yantai Development Zone, Shandong Patentee before: Sun Minfu |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Liu Heping Document name: Notification that Application Deemed not to be Proposed |
|
C56 | Change in the name or address of the patentee |
Owner name: NEIMENGGU YITAI PHARMACY CO.,LTD. Free format text: FORMER NAME: INNER MONGOLIA YITAI BIOLOGICAL HI-TECH CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: Inner Mongolia city Dongsheng District Tianjiao road Ordos Yitai building Patentee after: Inner Monglia Yicai Pharmaceutical Co., Ltd. Address before: Erdos West Street, Erdos District, Erdos City, Inner Mongolia, Dongsheng Patentee before: Inner Mongolia Yitai bio Tech Co. Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: INNER MONGOLIA KANG'ENBEI PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: INNER MONGLIA YICAI PHARMACEUTICAL CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: Hangjinqi town the Inner Mongolia Autonomous Region City State Road 109 North 017400 Erdos Patentee after: Inner Mongolia Kang'enbei Pharmaceutical Co., Ltd. Address before: 017000 Erdos the Inner Mongolia Autonomous Region District of Dongsheng City Road Tianjiao Yitai building Patentee before: Inner Monglia Yicai Pharmaceutical Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SHENGLONG BRANCH OF INNER MONGOLIA KANG'EN PHARMAC Free format text: FORMER OWNER: INNER MONGOLIA KANG'ENBEI PHARMACEUTICAL CO., LTD. Effective date: 20150821 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150821 Address after: Hangjinqi town 017400 the Inner Mongolia Autonomous Region City 109 State Road, North Road, Erdos SINJ East Patentee after: Inner Mongolia Conba Pharmaceutical Co. Ltd. Shenglong branch Address before: Hangjinqi town the Inner Mongolia Autonomous Region City State Road 109 North 017400 Erdos Patentee before: Inner Mongolia Kang'enbei Pharmaceutical Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170405 Address after: 017400 Inner Mongolia city Erdos Hangjinqi Seney town 109 State Road, North Road East Patentee after: Inner Mongolia Kang'enbei Pharmaceutical Co., Ltd. Address before: Hangjinqi town 017400 the Inner Mongolia Autonomous Region City 109 State Road, North Road, Erdos SINJ East Patentee before: Inner Mongolia Conba Pharmaceutical Co. Ltd. Shenglong branch |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040526 Termination date: 20190825 |
|
CF01 | Termination of patent right due to non-payment of annual fee |